Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
about
Bioengineering strategies for designing targeted cancer therapiesInfluence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.Quantitative Accuracy of Low-Count SPECT Imaging in Phantom and In Vivo Mouse Studies.Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptidesDevelopment of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptorCurrent Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Radiometallated peptides for molecular imaging and targeted therapy.Radiopharmaceutical development of radiolabelled peptides.Radiolabelled peptides for oncological diagnosis.[(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation.rG17PE38, a novel immunotoxin target to gastric cancer with overexpressed CCK-2R.Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.Exploiting the Concept of Multivalency with 68Ga- and 89Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression.Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression
P2860
Q34194191-4D1CEA1B-C12A-419B-8A47-2DD9E91AC2E0Q34250142-3A028BDE-0BC3-4D75-8B25-0B0402ED7EE8Q34982377-31E2A915-1D56-4FDC-81B7-DD38E64D0D94Q35043734-572F3A22-0C30-49C1-AD56-9BE0BC0514B7Q35078943-F23385A2-87F5-4F1A-AF45-AD83E98D29AEQ35235477-3FC518C1-C147-4855-8721-3A2933D41EFBQ37731335-14C64764-BF1E-42FB-AE61-D611A3A8C28FQ37847064-B2C96D04-FEF1-4E15-99BC-1F4190CF63DBQ37990399-BCD6F1DC-5BD1-4A72-86AB-D7396E35BEFAQ37990405-D021F97E-8526-4091-9841-2A14ED08E27CQ38933775-5ECEC7D8-C6F4-47ED-8B90-2DD9E426A5C2Q39212203-BB0DE1CD-87BA-42DB-82D3-470E1F43CB53Q39552291-9BEB290F-13A8-40E6-9B2B-CA5D0CF529E1Q55263067-56F345DA-806D-45F9-A303-7BF605365603Q57757444-54BF91F3-4375-4DC8-A618-4543E48E6AD8
P2860
Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@en
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@nl
type
label
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@en
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@nl
prefLabel
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@en
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@nl
P2093
P1476
Targeting of CCK-2 receptor-ex ...... eled divalent gastrin peptide.
@en
P2093
Ciara Finucane
David Ellison
Jane K Sosabowski
Julie M Foster
Stephen J Mather
Susan A Watson
Torkjel Matzow
P304
P356
10.2967/JNUMED.109.064808
P407
P577
2009-11-12T00:00:00Z